AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$BLSM

BlossomHill Therapeutics, Inc.

Price · $BLSMvia TradingView
AI sentiment · 7d1 articles
AUG 22net (bullish − bearish)AUG 28
Bullish
1
Neutral
0
Bearish
0
Insider · 30dAll trades →
Buys
$25.2M
7 txs
Sells
—
0 txs
Liptak Vincent Paul2× · $75K
10b5-1 share of filings0%
See all $BLSM insider activity →
Top stories · $BLSMMore →
AUG 28·rttnews.comHigh

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

AUG 18·finanznachrichten.de

BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

BlossomHill Therapeutics (Nasdaq: BLSM) said the FDA granted Fast Track designation to BH-30643 for advanced or metastatic EGFR C797S-positive NSCLC after prior third-generation EGFR TKI treatment. BH-30643 is in the SOLARA Phase 1/2 first-in-human trial (NCT06706076) across 40+ sites in 10 countries.

BLSM sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning BLSM (BlossomHill Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent BLSM coverage spans insider activity, market movers and regulation.

In the last 30 days, BLSM insiders filed 7 SEC Form 4 transactions — 7 purchases ($25.2M) and no sales. The most active reporter was Liptak Vincent Paul, General Counsel, with 2 filings.

What's driving BLSM

  • Fast Track status accelerates development and may attract investors.

    rttnews.com · Aug 28, 2026

  • Fast Track can accelerate FDA interactions and potentially enable rolling review and expedited pathways, improving near-term regulatory optionality for BH-30643.

    finanznachrichten.de · Aug 18, 2026

  • The filing is a fresh insider purchase datapoint, but it is not a fundamental catalyst like earnings, guidance, or a deal.

    SEC EDGAR · Aug 12, 2026

  • This is an insider-related Form 4 purchase, but it is indirect and not a 10b5-1 plan, so it is more sentiment than a fundamental catalyst.

    SEC EDGAR · Aug 12, 2026

  • This is a routine insider open-market purchase with no 10b5-1 plan, but it is not a fundamental catalyst by itself.

    SEC EDGAR · Aug 10, 2026

alphai scores every news story that mentions BLSM with an AI model for sentiment and relevance, and aggregates insider trades from BlossomHill Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BLSM

Score
AUG 28$NEOHighAI 8/10rttnews.com

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

4 min read
AUG 18$BLSMMedAI 8/10finanznachrichten.de

BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

BlossomHill Therapeutics (Nasdaq: BLSM) said the FDA granted Fast Track designation to BH-30643 for advanced or metastatic EGFR C797S-positive NSCLC after prior third-generation EGFR TKI treatment. BH-30643 is in the SOLARA Phase 1/2 first-in-human trial (NCT06706076) across 40+ sites in 10 countries.

4 min read

Related tickers

More in Biotechnology